

### **Bibliography**

- BioMarin press release. BioMarin to Provide Update to Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A at 35th Annual J.P. Morgan Healthcare Conference. <http://investors.biomin.com/2017-01-08-BioMarin-to-Provide-Update-to-Proof-of-Concept-Data-for-BMN-270-Gene-Therapy-in-Hemophilia-A-at-35th-Annual-J-P-Morgan-Healthcare-Conference>. January 8, 2017. Accessed March 9, 2017.
- Bowman ML, James PD. Bleeding scores for the diagnosis of von Willebrand Disease. *Semin Thromb Hemost*. 2017 Feb 14 [epub ahead of print].
- Buckner T, Witkop M, Guelcher C, et al. Psychosocial impact of mild to severe haemophilia B on affected adults and children: methods and demographics of the bridging haemophilia B experiences results and opportunities into solutions (B-HERO-S) study. Presented at: World Federation of Hemophilia Congress; July 24-28, 2016; Orlando, FL. Abstract PO-T-26.
- Cutter S, Molter D, Dunn S, et al. Impact of mild to severe haemophilia on education and work by US adult men and women and caregivers of children with haemophilia B: the bridging hemophilia B experiences results and opportunities into solutions (B-HERO-S) study. Presented at: 2016 World Federation of Hemophilia Congress; July 24-28, 2016; Orlando, FL. Abstract PO-T-24.
- Escobar MA, Tehranchi R, Karim FA, et al. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. *Haemophilia*. 2016;23:67-76.
- Faiz AS, Kaveney A, Guo S, et al. Screening of female family members of von Willebrand disease patients: utility of a modified screening tool in a high-risk population. *Haemophilia*. 2017 Feb 8 [Epub ahead of print].
- Fischer K, Poonnoose P, Dunn AL, et al. Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective. *Haemophilia*. 2017;23:11-24.
- Fischer K, Nijdam A, Holmström M, et al. Evaluating outcome of prophylaxis in haemophilia: objective and self-reported instruments should be combined. *Haemophilia*. 2016;22:e80-e86.
- George LA, Fogarty PF. Gene therapy for hemophilia: past, present and future. *Semin Hematol*. 2016;53:46-54.
- George LA, Sullivan SK, Giermasz A, et al. Adeno-associated virus mediated gene transfer for hemophilia B achieves sustained mean factor IX activity levels of >30% without immunosuppression. *Blood*. 2016;128 (abstract 3).

Giangrande P. The future of hemophilia treatment: longer-acting factor concentrates versus gene therapy. *Semin Thromb Hemost.* 2016;42:513-517.

Haley K, Sidonio R, Cheng D, et al. A cross-sectional study of females with congenital bleeding disorders enrolled in the ATHNdataset. Presented at: 2016 World Federation of Hemophilia Congress; July 24-28, 2016; Orlando, FL. Abstract 35.

Hartmann I, Croteau SE. 2017 Clinical trials update: Innovations in hemophilia therapy. *Am J Hematol.* 2016;91:1252-1260.

Huth-Kuehne A, Klamroth R, Khair K, et al. Striving for a bleed free world: an interim analysis from the AHEAD study. *Haemophilia.* 2016;22(suppl 2):44 (abstract P067).

Johnsen J, Fletcher SN, Huston H, et al. F8 and F9 gene variants, CADD scores, and hemophilia severity: in the My Life, Our Future genotyping project. *Int Soc Thromb Haemost.* 2015;13(suppl 2):209 (abstr OR298).

Konkle BA, Johnsen JM, Ruuska S, et al. Analysis of F8 and F9 variants in the first 3000 hemophilia A and B patients in the My Life, Our Future project. *Thromb Hemost Soc NA.* 2016 (abstract F13).

Kulkarni R, Presley RJ, Lusher JM, et al. Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System. *Haemophilia.* 2016 Nov 4 [Epub ahead of print].

Kumar R, Dunn A, Carcao M. Changing paradigm of hemophilia management: extended half-life factor concentrates and gene therapy. *Semin Thromb Hemost.* 2016;42:18-29.

Ljung R, Fischer K, Carcao M, et al. Practical considerations in choosing a factor VIII prophylaxis regimen: role of clinical phenotype and trough levels *Thromb Haemost.* 2016;115:913-920.

Manco-Johnson MJ, Soucie JM, Gill JC. Prophylaxis usage, bleeding rates and joint outcomes of hemophilia 1999 - 2010: a surveillance project. *Blood.* 2017 Feb 9 [Epub ahead of print].

Mannucci PM, Franchini M. Laboratory monitoring of replacement therapy for major surgery in von Willebrand disease. *Haemophilia.* 2017 Jan 22 [Epub ahead of print].

Mazepa MA, Monahan PE, Baker JR, et al. Men with severe hemophilia in the United States: birth cohort analysis of a large national database. *Blood.* 2016;127:3073-3081.

Négrier C, Abdul Karim F, Lepatan LM, et al. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery. *Haemophilia.* 2016;22:e259-266.

Payne AB, Ghaji N, Mehal JM, et al. Mortality Trends and causes of death in persons with hemophilia, United States, 1999-2010. *Thromb Hemost Soc NA*. 2016 (abstract F55).

Pruthi RK. Laboratory monitoring of new hemostatic agents for hemophilia. *Semin Hematol*. 2016;53:28-34.

Quon D, Witkop M, Buckner TW, et al. Assessments of pain in US adults with haemophilia across patient-reported outcomes in the Pain, Functional Impairment, and Quality of Life (P-FiQ) study. Presented at: 2016 World Federation of Hemophilia Congress; July 24-28, 2016; Orlando, FL. Abstract P-W-129.

Recht M, Konkle BA, Jackson S, et al. Recognizing the need for personalization of haemophilia patient-reported outcomes in the prophylaxis era. *Haemophilia*. 2016;22:825-832.

Sidonio RF, Barry V, DeBaun M, et al. Reported bleeding among females with FVIII/FIX deficiency and type 1 von Willebrand disease: results from the female UDC. *Thromb Hemost Soc NA*. 2016 (abstract 50).

Skinner MW, Curtis R, Frick N, et al. The Patient Reported Outcomes, Burdens, and Experiences (PROBE) phase 1 study: methodology and feasibility. *Haemophilia*. 2016;22(suppl 2):43 (abstract P039).

Tiefenbacher S, Robinson MM, Ross EL, et al. Comparison of FVIII activity of select novel recombinant FVIII replacement products in commonly used FDA approved one-stage clot assay systems. *Int Soc Thromb Haemost*. 2015;13(suppl 2):566 (abstract PO161).

Ward P, Walsh CE. Current and future prospects for hemophilia gene therapy. *Expert Rev Hematol*. 2016;9:649-659.

Witkop M, Hernandez G, Recht M, et al. Assessments of functional impairment in US adults with haemophilia across patient-reported outcomes in the Pain, Functional Impairment, and Quality of Life (P-FiQ) study. Presented at: 2016 World Federation of Hemophilia Congress; July 24-28, 2016; Orlando, FL. Abstract P-M-131.

Young G, Carmona R, Vasquez S. Individualizing hemophilia prophylaxis using thromboelastography (HIP TEG). *Int Soc Thromb Haemost*. 2015;13(suppl 2):52-53 (abstract FVIII26).

Young G, Collins PW, Colberg T, et al. Nonacog beta pegol (N9-GP) in haemophilia B: a multinational phase III safety and efficacy extension trial (paradigm™4). *Thromb Res*. 2016;141:69-76.